Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma (SIMPLY)

15 novembre 2026 aggiornato da: University Health Network, Toronto

SIMulation-free Protocols for Lymphoma RadiotherapY [SIMPLY]

This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.

The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.

Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.

On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.

The study includes two cohorts:

Participants with orbital or ocular adnexal indolent B-cell lymphoma.

Participants with non-orbital indolent B-cell lymphoma.

If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.

The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.

Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X6
        • Reclutamento
        • Princess Margaret Cancer Centre, University Health Network
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologically confirmed indolent B-cell lymphoma, including marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma grades 1-2, small lymphocytic lymphoma, or mantle cell lymphoma.
  • Disease requiring focal radiation therapy with 4 Gy delivered in one fraction for local control or symptom relief.
  • Lesion anatomy suitable for single-fraction radiation therapy and simulation-free, CBCT-guided treatment delivery, as determined by the treating radiation oncologist.
  • Available diagnostic CT imaging suitable for contouring and dose calculation that encompasses the full intended target and relevant organs at risk:
  • Obtained within 2 months before treatment for orbital or ocular adnexal disease.
  • Obtained within 6 weeks before treatment for non-orbital disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, with the ability to tolerate treatment positioning and delivery.
  • Localized or advanced-stage disease is permitted, provided the target lesion is appropriate for focal treatment.

Exclusion Criteria:

  • Diagnostic imaging that does not meet the minimum quality requirements for treatment planning or falls outside the required time window.
  • Disease anatomy unsuitable for simulation-free delivery, such as inability to maintain stable positioning, excessive motion, or inadequate CBCT visualization.
  • Prior radiation therapy to the same site if re-irradiation using the study workflow is considered clinically inappropriate.
  • Bulky disease greater than 6 centimeters for which single-fraction 4 Gy radiation therapy is unlikely to provide adequate local control, as determined by the treating physician.
  • Requirement for urgent systemic therapy because of widespread or symptomatic disease.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Simulation-Free Single-Fraction Radiation Therapy

Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment.

Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.

Altri nomi:
  • Ultra-Low-Dose Radiation Therapy
  • CBCT-Guided Adaptive Radiation Therapy
  • Diagnostic CT-Based Radiation Treatment Planning

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Successful Completion of Simulation-Free Radiation Therapy
Lasso di tempo: Periprocedural (single radiation treatment session)

Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation.

Periprocedural (single radiation treatment session)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time From Radiation Oncology Consultation to Treatment
Lasso di tempo: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks

Number of calendar days between the radiation oncology consultation date and the date of radiation treatment.

From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
Same-Day Treatment
Lasso di tempo: Day 1 (date of radiation oncology consultation)

Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation.

Day 1 (date of radiation oncology consultation)
Total On-Couch Time
Lasso di tempo: Periprocedural (single radiation treatment session)

Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery.

Periprocedural (single radiation treatment session)
Number of Hospital Visits
Lasso di tempo: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks

Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow.

From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
CT Simulation Avoided
Lasso di tempo: Periprocedural (through completion of the single radiation treatment session)

Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment.

Periprocedural (through completion of the single radiation treatment session)
Reasons for Simulation-Free Workflow Failure
Lasso di tempo: From treatment planning through radiation treatment completion, up to 4 weeks

Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan.

From treatment planning through radiation treatment completion, up to 4 weeks
Clinician-Graded Treatment-Related Toxicity
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment

Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported.

Baseline, 2-4 weeks, and 3 months after treatment
Ocular Surface Disease Index Score
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment

Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment.

Baseline, 2-4 weeks, and 3 months after treatment
Head and Neck Quality-of-Life Symptoms
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment

Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites.

Baseline, 2-4 weeks, and 3 months after treatment
Index Symptom Severity
Lasso di tempo: Baseline, 2-4 weeks, and 3 months after treatment

Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom.

Baseline, 2-4 weeks, and 3 months after treatment
Local Control of the Treated Site
Lasso di tempo: 6 months after radiation treatment

Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination.

6 months after radiation treatment
Retreatment of the Treated Site
Lasso di tempo: Within 12 months after radiation treatment

Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site.

Within 12 months after radiation treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 ottobre 2026

Completamento primario (Stimato)

31 dicembre 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

27 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 26-5319

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .